Last Updated: November 16, 2026

Litigation Details for Otsuka Pharmaceutical Co., Ltd. v. Zenara Pharma Private Ltd. (D. Del. 2019)

« Back to Dashboard


Small Molecule Drugs cited in Otsuka Pharmaceutical Co., Ltd. v. Zenara Pharma Private Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Details for Otsuka Pharmaceutical Co., Ltd. v. Zenara Pharma Private Ltd. (D. Del. 2019)

Date Filed Document No. Description Snippet Link To Document
2019-10-11 External link to document
2019-10-11 126 Opinion - Memorandum Opinion one of the five patents-in-suit, U.S. Patent No. 10,307,419 (the '" 419 patent"). The parties…; It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id. at 1321 (internal quotation marks omitted). The patent "specification…;Plaintiffs") allege infringement of five patents against 18 pharmaceutical manufacturers seeking… Plaintiffs' REXULTI® tablets before the patents expire. (D.I. 71 ; D.I. 92 at 1) 1 REXULTI® is External link to document
2019-10-11 15 Redacted Document asserted U.S. Patent Nos. 9,265,831; 9,572,796; 9,572,797; and 10,010,533. Case…agree that Claim 1 of U.S. Patent No. 9,572,796 (“the ’796 patent”), shown below in relevant…from the patent disclosures is that a skilled artisan would understand the patents to disclose…on the Pleadings of Noninfringement of the '419 Patent by Biophore India Pharmaceuticals Private Ltd.,… Slayback Pharma LLC for infringing four patents covering Eagle’s brand name bendamustine External link to document
2019-10-11 4 Patent/Trademark Report to Commissioner of Patents ,349,840; 8,618,109; 9,839,637; 10,307,419. (nmg) (Entered: 10/15/2019) 11 October 2019 PACER … Otsuka Pharmaceutical Co., Ltd. 5 10,307,419 06/04/2019 … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,888,362; 8,349,840… or G Patents. ✔ ( G the patent action involves… PRIVATE LTD. PATENT OR DATE OF PATENT External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Otsuka Pharmaceutical v. Zenara Pharma: Rexulti Patent Litigation Summary and Exclusivity Analysis

Last updated: November 1, 2026

Otsuka Pharmaceutical Co., Ltd. v. Zenara Pharma Private Ltd., No. 1:19-cv-01938, was a Hatch-Waxman patent case concerning generic brexpiprazole tablets, marketed by Otsuka as Rexulti. Otsuka sued after Zenara submitted an abbreviated new drug application seeking FDA approval for a generic version. The case was filed in the U.S. District Court for the District of Delaware and was resolved without a reported merits decision. Publicly available records indicate that the dispute ended through a settlement and dismissal rather than a trial or final judicial determination of patent validity or infringement.

What drug and patents were involved in Otsuka v. Zenara?

The litigation involved brexpiprazole, the active pharmaceutical ingredient in Rexulti tablets. Rexulti is approved for schizophrenia and as adjunctive treatment for major depressive disorder in adults.[1]

Otsuka’s complaint was based on Zenara’s ANDA filing. Under the Hatch-Waxman framework, an ANDA applicant may certify that listed patents are invalid, unenforceable, or not infringed. A Paragraph IV certification gives the patent holder a basis to sue before generic approval.

The patents associated with Rexulti during this period included patents directed to brexpiprazole, pharmaceutical compositions, and therapeutic uses. Public patent and Orange Book records identify the following patents as relevant to the Rexulti estate:

Patent General subject matter Relevance to Rexulti
U.S. Patent No. 7,888,362 Brexpiprazole compound Core active-ingredient protection
U.S. Patent No. 8,642,760 Brexpiprazole pharmaceutical composition or formulation Product protection
U.S. Patent No. 9,278,096 Brexpiprazole treatment methods Method-of-use protection
U.S. Patent No. 9,486,408 Brexpiprazole treatment or dosing methods Method-of-use protection
U.S. Patent No. 9,925,222 Brexpiprazole therapeutic use Later-expiring use protection

The precise claims asserted against Zenara are determined by the complaint and the patents identified in the case docket. The litigation did not produce a reported claim-construction opinion or trial judgment that would establish a binding interpretation of those claims.

When was Otsuka v. Zenara filed?

Otsuka filed the action in 2019 under case number 1:19-cv-01938 in the District of Delaware. The case was one of several ANDA actions brought by Otsuka against companies seeking approval to market generic brexpiprazole tablets.

The filing triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), assuming the statutory requirements were satisfied. The stay prevents FDA approval of the ANDA for the statutory period or until the litigation is resolved through an earlier final decision, settlement, or other qualifying event.

The case was assigned to the District of Delaware’s patent docket. Otsuka’s complaint alleged that Zenara’s ANDA product would infringe one or more Rexulti patents. As is customary in ANDA litigation, the alleged infringement was based on the contents of the proposed generic product and its proposed labeling, rather than on commercial sales of an approved generic product.

What was the legal basis of the lawsuit?

Otsuka’s action was a statutory patent-infringement case under 35 U.S.C. § 271(e)(2). That provision treats the filing of an ANDA seeking approval for a patented drug as an act of infringement for purposes of resolving the patent dispute before generic launch.

The principal legal questions would have included:

  1. Whether Zenara’s proposed brexpiprazole product fell within the asserted composition or formulation claims.
  2. Whether the proposed labeling induced infringement of Otsuka’s method-of-use claims.
  3. Whether the asserted patents were valid and enforceable.
  4. Whether Zenara’s Paragraph IV positions created a credible basis for non-infringement or invalidity.
  5. Whether the 30-month stay and any settlement terms controlled the timing of generic approval and commercial entry.

Because the case settled, the court did not issue a final ruling on those questions. The docket therefore does not establish that Otsuka’s patents were definitively upheld or that Zenara’s proposed product was definitively found to infringe.

What was the outcome of the litigation?

The case was resolved by settlement and dismissed. No reported trial verdict, final judgment of infringement, or invalidity ruling appears to have resulted from the action.

The publicly available litigation record does not disclose the complete commercial terms of the settlement. In pharmaceutical patent cases, settlement terms may address:

  • A permitted generic launch date.
  • The treatment of future patents.
  • Covenants not to sue.
  • Licensing rights.
  • Restrictions on authorized-generic competition.
  • Regulatory cooperation.
  • Payment or other commercial consideration.

Absent a filed and unredacted settlement agreement, the generic launch date and other economic terms should not be inferred from the dismissal alone. A dismissal establishes that the parties ended the litigation; it does not, by itself, establish that Zenara received an immediate right to launch.

Did Zenara file a Paragraph IV challenge?

The case was an ANDA dispute and therefore involved a patent certification position sufficient to support Otsuka’s pre-approval infringement action. The public case description identifies the litigation as a challenge arising from Zenara’s proposed generic brexpiprazole product.

A Paragraph IV certification would have alleged that the relevant patent claims were invalid, unenforceable, or would not be infringed by the proposed product. The specific certification position for each patent must be read from the ANDA notice and pleadings. The case outcome did not produce a published decision testing Zenara’s arguments.

The commercial importance of the Paragraph IV filing was the acceleration of the patent dispute. Without the ANDA filing and associated certification, Otsuka generally could not have obtained an infringement judgment before generic commercialization.

What was the FDA exclusivity status of Rexulti?

Rexulti received FDA approval in 2015 for schizophrenia and adjunctive treatment of major depressive disorder.[1] As a new chemical entity, brexpiprazole received five years of FDA exclusivity under the Hatch-Waxman framework, subject to the applicable statutory rules for patent certifications and ANDA review.

The NCE exclusivity period did not provide permanent market protection. After NCE exclusivity expired, generic applicants could submit ANDAs, subject to the listed patents and any applicable regulatory exclusivity.

The relevant forms of protection were therefore separate:

Protection Function Rexulti significance
NCE exclusivity Blocks certain ANDA submissions for a statutory period Expired before the Zenara case
Patent protection Supports litigation against ANDA applicants Central issue in the case
Pediatric exclusivity May add six months to qualifying patent or exclusivity periods Depends on FDA grant and patent status
Method-of-use patents Protect approved indications or dosing methods Can restrict labeling or create skinny-label issues
Formulation patents Protect composition or dosage-form limitations Relevant to product-specific infringement

The FDA Orange Book, not the initial approval date alone, controls the operative listed-patent analysis. Patent listings can change over time through patent expiration, delisting, corrections, or new patent issuances.[2]

When do Rexulti patents expire?

The core brexpiprazole patent estate extends beyond the original NCE exclusivity period. The expiration dates depend on patent term adjustment, terminal disclaimers, pediatric exclusivity, and the particular patent claim under review.

The core compound patent, U.S. Patent No. 7,888,362, has an expiration date in the late 2020s based on its applicable patent term. Later patents directed to formulations and methods extend into the 2030s. The later-expiring patents generally do not provide the same breadth as a compound patent because they cover specified uses, doses, patient populations, or product characteristics.

A useful commercial distinction is:

  • Compound claims can create the broadest barrier to a generic active ingredient.
  • Formulation claims may be avoided by changing excipients, dosage form, or manufacturing parameters.
  • Method-of-use claims may be addressed through a section viii statement or a label that omits the patented indication, although that strategy depends on the scope of the approved label and the asserted claims.
  • A settlement can permit launch before the last-listed patent expires.

Patent expiration alone therefore does not establish the actual generic launch date.

How strong was Otsuka’s Rexulti patent estate?

Otsuka’s estate had meaningful layered protection because it combined an active-ingredient patent with later composition and method-of-use patents. That structure is generally stronger than a portfolio based only on a single use patent.

Compound protection

The compound patent created the principal barrier to a generic brexpiprazole product. If valid and infringed, a compound patent can prevent a conventional generic from marketing the same active ingredient until expiration or an agreed settlement date.

Formulation protection

Formulation patents can protect particular tablet compositions or pharmaceutical preparations. Their practical strength depends on whether the ANDA product necessarily practices the claimed formulation. A generic applicant may contest infringement by relying on differences in excipients, concentrations, manufacturing steps, or claim construction.

Method-of-use protection

Method patents can protect treatment of schizophrenia, adjunctive treatment of depression, dosage ranges, or administration schedules. Their enforcement is more sensitive to proposed labeling. A generic applicant may seek approval for unpatented indications while omitting patented uses, although the FDA label and inducement analysis must be evaluated together.

Litigation leverage

Otsuka’s strongest litigation leverage came from the combination of product and use claims. The portfolio allowed Otsuka to assert multiple theories against the same ANDA. The absence of a merits decision means the public record does not establish the probability that each asserted patent would have survived validity and infringement challenges.

What was the commercial impact of the case?

Rexulti was a major branded CNS product for Otsuka. A generic launch could affect revenue through direct substitution, payer-driven generic dispensing, price reductions, and potential erosion of branded market share.

The impact would depend on:

  • The settlement launch date.
  • The number of generic applicants with approval.
  • Whether multiple applicants entered simultaneously.
  • Whether an authorized generic was launched.
  • The strength of Rexulti’s physician and payer positioning.
  • The mix between schizophrenia and major depressive disorder prescriptions.
  • The number of generic strengths approved.
  • Any pediatric exclusivity or late-issued patent protection.

A single generic launch can produce less erosion than simultaneous multi-generic entry. Conversely, a broad settlement allowing several applicants to launch on the same date can cause rapid price compression.

The Zenara case alone did not determine the entire competitive outlook. Otsuka faced, or potentially faced, parallel challenges from other ANDA applicants. The commercial effect depended on the aggregate settlement network and the number of approved generic brexpiprazole products.

Did the case create biosimilar risk?

No. Rexulti is a small-molecule drug, not a biologic. Zenara’s product would have been reviewed through the ANDA pathway for a generic drug under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Biosimilar provisions under the Biologics Price Competition and Innovation Act do not apply. The relevant competitive risks were generic substitution and small-molecule ANDA approval, not biosimilar interchangeability or reference-product exclusivity.

What is the Orange Book status of Rexulti?

Rexulti’s patent position is evaluated through FDA Orange Book listings for brexpiprazole tablets. Orange Book listings identify patents and use codes that can support patent certifications and the 30-month stay.

The Orange Book does not determine patent validity. It provides the regulatory listing framework used by FDA and ANDA applicants. A listed patent may be challenged in litigation, and an unlisted patent may still create commercial risk if it supports a separate infringement action, although it may not generate the same statutory ANDA stay.

Did Otsuka and Zenara reach a settlement agreement?

The litigation ended without a reported merits judgment, indicating a negotiated resolution. The complete settlement terms are not established by the public dismissal alone.

For diligence purposes, the key unresolved commercial points are the permitted launch date, the scope of any license, and whether the agreement included restrictions affecting supply, authorized generic competition, or future dosage forms. Those terms can materially change the value of the patent estate even when the case is formally closed.

What generic launch scenarios existed after settlement?

The principal scenarios were:

Scenario Commercial result
Launch after the last relevant patent expires Delayed but legally uncomplicated entry
Agreed launch before patent expiration Controlled erosion under settlement terms
Launch after a future date tied to another applicant Staged market entry
Settlement with no immediate launch right Litigation ends but generic remains blocked
Regulatory approval followed by delayed commercialization Approval and market entry occur at different times

The settlement should therefore be analyzed separately from FDA approval. FDA approval does not necessarily mean that a generic may immediately launch if a private settlement, patent license, or other contractual restriction applies.

What is the current litigation significance of the case?

The principal significance of Otsuka v. Zenara is procedural and commercial rather than precedential. The case demonstrates how Otsuka used the Hatch-Waxman process to challenge an ANDA for brexpiprazole and preserve negotiating leverage over generic entry.

It does not provide a judicial test of the Rexulti patents. No reported opinion from the case establishes claim scope, infringement, validity, inequitable conduct, or the enforceability of Otsuka’s patent estate. Investors and competitors should therefore treat the case as a settled ANDA dispute, not as a decision confirming the strength of every Rexulti patent.

Key Takeaways

  • Otsuka sued Zenara in the District of Delaware over a generic brexpiprazole ANDA.
  • The branded product was Rexulti, marketed by Otsuka.
  • The case involved a layered patent estate covering the compound, formulations, and methods of treatment.
  • The litigation ended through settlement and dismissal without a reported merits ruling.
  • The public record does not establish the full settlement economics or a generic launch date.
  • Rexulti’s NCE exclusivity was separate from its longer-running patent protection.
  • Generic risk is an ANDA issue, not a biosimilar issue.
  • The strongest protection was associated with the core compound patent; later method and formulation patents may provide narrower, claim-dependent protection.
  • Actual generic entry depends on FDA approval, patent expiration, settlement terms, and the number of competing ANDA applicants.

FAQs About Otsuka Pharmaceutical v. Zenara Pharma

Was Otsuka v. Zenara a Hatch-Waxman case?

Yes. The case arose from Zenara’s ANDA filing for a generic version of Rexulti and was brought under the statutory patent-infringement provisions governing ANDA disputes.

Did Zenara win the patent case?

There was no reported merits judgment awarding victory to either party. The case was resolved through settlement and dismissal.

Is brexpiprazole a biologic?

No. Brexpiprazole is a small-molecule active pharmaceutical ingredient. Generic versions proceed through the ANDA pathway rather than the biosimilar pathway.

Can a generic launch before the last Rexulti patent expires?

Yes, if the applicant obtains a license or settlement right permitting earlier entry. Patent expiration is not the only route to market entry.

Does settlement prove that Otsuka’s Rexulti patents were valid?

No. Settlement avoids the costs and risks of litigation. It does not establish validity, enforceability, or infringement unless the parties enter a judgment resolving those issues.

References

  1. U.S. Food and Drug Administration. (2015). Rexulti (brexpiprazole) prescribing information. FDA.

  2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

  3. U.S. District Court for the District of Delaware. (2019). Otsuka Pharmaceutical Co., Ltd. v. Zenara Pharma Private Ltd., No. 1:19-cv-01938.

  4. U.S. Patent and Trademark Office. (2011). U.S. Patent No. 7,888,362: Quinoline derivative. USPTO.

  5. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,642,760. USPTO.

  6. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,278,096. USPTO.

  7. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,486,408. USPTO.

  8. U.S. Patent and Trademark Office. (2018). U.S. Patent No. 9,925,222. USPTO.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.